Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...
News245h
The Global Fund will roll out the twice-yearly anti-HIV jab – with or without Pepfar
The Global Fund to Fight AIDS, Tuberculosis and Malaria says it will fund the rollout of the twice-yearly anti-HIV jab, ...
Gilead price target raised to $132 from $115 at Oppenheimer
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
HHS increasing scrutiny of vaccines under RFK Jr., WSJ reports
The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...
‘The Handmaid’s Tale’ Sequel ‘The Testaments’ Casts Lucy Halliday As Co-Lead Daisy
Lucy Halliday (Blue Jean) has been tapped as a lead opposite Chase Infiniti and Ann Dowd in The Handmaid’s Tale sequel The ...
Harnessing innovation to accelerate progress and end the HIV epidemic by 2030
Innovation in HIV care and prevention is transforming the fight, but there is more to be done in order to meet the UNAIDS targets of ending the HIV epidemic by 2030 ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.
Le Lézard6d
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
In February 2025, Immix Biopharma, Inc. announced that the FDA has granted RMAT designation to its sterically-optimized CAR-T therapy, NXC-201, for the treatment of relapsed or refractory AL ...